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Abstract
Objective: Leukotriene D4 (LTD4) causes contraction of the cat lower esopha-
geal sphincter. The effects of leukotrienes in the guinea pig lower esopha-
geal sphincter and the cysteinyl leukotriene receptor (CysLT) subtype that 
mediate this contraction are not known. The purpose of the present study 
was to characterize the CysLT receptors in the guinea pig lower esophageal 
sphincter.
Materials and Methods: We measured the contractions of transverse 
strips from the guinea pig lower esophageal sphincter caused by cysteinyl 
leukotrienes, LTC4, LTD4 and LTE4, and the dihydroxy leukotriene, LTB4. 
We also measured LTD4-induced contraction inhibited by CysLT receptor 
antagonists, tetrodotoxin and atropine.
Results: In the guinea pig lower esophageal sphincter strips, LTC4, LTD4 
and LTE4, but not LTB4, caused concentration-dependent contractions. 
The relative potencies for cysteinyl leukotrienes to cause contraction were 
LTD4 = LTC4 > LTE4. LTE4 was a partial agonist. The LTD4-induced contraction 
was inhibited by two selective CysLT1 receptor antagonists, montelukast 
and zafirlukast, and by the dual CysLT1 and CysLT2 receptor antagonist BAY 
u9773. The combination of both montelukast and BAY u9773 did not poten-
tiate the inhibition caused by montelukast alone. These findings indicate 
that CysLT1 mediates the contraction in the lower esophageal sphincter. 
Furthermore, LTD4-induced contraction was not affected by tetrodotoxin 
or atropine, suggesting a direct effect.
Conclusion: These results demonstrate that cysteinyl leukotrienes, but 
not the dihydroxy leukotriene LTB4, cause contraction of the guinea pig 
lower esophageal sphincter. The CysLT1 receptor mediates this contraction. 
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1. Introduction
Cysteinyl leukotrienes (Cys-LTs), such as LTC4, LTD4, 
and LTE4, and the dihydroxy leukotriene, LTB4, are 
inflammatory mediators that are derived from the 
lipoxygenase pathway of arachidonic acid metabolism. 
Cysteinyl leukotrienes are peptide-conjugated lipids 
and are produced by eosinophils, basophils, mast cells, 
and macrophages [1–3]. They were identified on the 
basis of their contractile properties for intestinal and 
bronchial smooth muscle, and they are potent inflam-
matory mediators. These cysteinyl leukotrienes play 
an important role in respiratory diseases such as asthma 
and allergic rhinitis, and have been implicated in other 
inflammatory conditions including cardiovascular, gas-
trointestinal, skin and immune disorders [1–3]. Two 
receptor subtypes for the cys-LTs, the type 1 and type 2 
cys-LT receptors (CysLT1 and CysLT2, respectively), have 
been cloned and characterized. CysLT1 receptors have 
been found in the spleen, lung, placenta and small 
intestine, whereas CysLT2 receptors have been found in 
the lung, spleen, heart, lymph nodes and brain [1–10]. 
The rank order of agonist potency at the CysLT1 re-
ceptor is LTC4 = LTD4 > LTE4, at which LTE4 is a partial 
agonist, or LTC4 = LTD4 = LTE4. The rank order of agonist 
potency at the CysLT2 receptor is LTC4 = LTD4 > > LTE4 
(LTE4 is inactive) [4–10]. Many selective antagonists for 
CysLT1 have been developed. These antagonists, includ-
ing montelukast, zafirlukast, pranlukast, pobilukast and 
MK571, block CysLT-induced calcium mobilization in 
CysLT1 receptor-transfected cells but not in cells trans-
fected with the CysLT2 receptor. On the other hand, 
selective CysLT2 receptor antagonists have not been 
reported to date. BAY u9773 is an antagonist at both 
the CysLT1 and CysLT2 receptors [1–4,11,12].
In the gastrointestinal system, CysLT1 receptors are 
expressed in the small intestine, colon, liver, and in 
cancers such as colorectal cancer, whereas CysLT2 
receptors are expressed in the stomach, small intestine, 
colon, liver and pancreas [1–4,6–9,13,14]. Cysteinyl 
leukotrienes have been implicated in inflammatory 
conditions including eosinophilic esophagitis and eosin-
ophilic gastroenteritis [1–3,15–18]. Previous studies 
have demonstrated that cysteinyl leukotrienes cause 
contraction of the cat esophagus and lower esophageal 
sphincter, and the rat stomach and colon, as well as 
the guinea pig ileum, colon and gallbladder [18–22]. 
In the guinea pig gallbladder, cysteinyl leukotrienes 
cause contractions through interaction with CysLT1 
receptors whereas in the guinea pig ileum, they cause 
contraction mainly through interaction with CysLT2 
receptors [1,4,12,18,19].
LTD4 has been demonstrated to cause contraction 
of the cat lower esophageal sphincter [20]. At the pres-
ent time, no data are available on the effects caused 
by leukotrienes in the guinea pig lower esophageal 
sphincter. Furthermore, the subtype of the cysteinyl 
leukotriene receptor mediating the contraction of 
the lower esophageal sphincter is unknown. We have 
demonstrated that the endothelin ETA receptor, ETB 
receptor, protease-activated receptor-1 (PAR1) and 
PAR2 mediate contraction or relaxation in the guinea 
pig lower esophageal sphincter [23,24]. The purpose 
of the present study was to characterize the CysLT 
receptors in the guinea pig lower esophageal sphincter, 
a ring of thickened circular muscle at the gastroesoph-
ageal junction [23].
2. Materials and methods
Male Hartley guinea pigs were obtained from the Animal 
Center, National Science Council, Taiwan. The leuko-
trienes LTB4, LTC4, LTD4 and LTE4, and the cysteinyl 
leukotriene antagonists montelukast, zafirlukast and 
BAY u9773, were purchased from Cayman Chemical 
(Ann Arbor, MI, USA). Carbachol, atropine and all buffer 
reagents were purchased from Sigma Chemical (St. 
Louis, MO, USA). Tetrodotoxin was obtained from Tocris 
Cookson (Avonmouth, Bristol, UK).
2.1. Measurement of contraction or 
relaxation of isolated lower 
esophageal sphincter strips
The Institutional Animal Care and Use Committee of 
Buddhist Tzu Chi General Hospital, Hualien, approved 
the protocol for this study. Male guinea pigs, weighing 
350–400 g, were sacrificed with CO2. The stomach, 
including a portion of the esophagus, was quickly re-
moved and placed in oxygenated standard incubation 
solution (see below). The esophagus and stomach were 
cut open in the longitudinal direction along the greater 
curvature and pinned flat with the mucosal side up. 
The mucosa was removed with micro-scissors. Trans-
verse strips (2 mm wide and 10 mm long) were cut from 
the area of the lower esophageal sphincter, which was 
easily identified as a thickened region of muscle be-
tween the esophagus and the stomach. In preliminary 
experiments, the thickening of the circular smooth 
muscle was confirmed by observing hematoxylin and 
eosin-stained tissue sections under a microscope (data 
not shown) [23].
Measurements of contraction and relaxation of iso-
lated lower esophageal sphincter strips from the guinea 
pig esophagus were performed as previously described 
[23,24]. In brief, the strips were placed in a standard 
incubation solution containing 118 mM NaCl, 25 mM 
NaHCO3, 4.7 mM KCl, 14 mM glucose, 1.2 mM NaH2PO4, 
1.8 mM CaCl2, gassed with 95% O2 • 5% CO2. The final 
pH at 37°C was 7.40 ± 0.05. The sphincter strips were 
attached to organ baths using surgical silk sutures and 
incubated at 37°C in the standard incubation solution 
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continuously gassed with 95% O2 • 5% CO2. The strips 
were connected to isometric transducers (FT.03; Grass 
Technologies, West Warwick, RI, USA), which were con-
nected to an amplifier (Gould Instrument Systems, 
Valley View, OH, USA) and a computer recording system 
(BIOPAC Systems, Goleta, CA, USA). The basal tension 
of the muscle strips was adjusted to 1.0 g [23,24]. Exper-
iments were started after a 45-minute equilibration 
period. All contraction experiments with agonists were 
performed in a cumulative manner because of the 
absence of immediate desensitization of the lower 
esophageal sphincter muscle to the cumulative ad-
ministration of these agents, similar to the guinea pig 
gallbladder [19]. Carbachol (1 μM)-induced contraction 
was used as a reference to express the contractile 
response to agonists. In the relaxation experiments, 
leukotrienes were added to the carbachol-contracted 
muscle strips. Carbachol-induced tone before the 
addition of leukotrienes was used as a reference to 
express relaxation to these agents. Carbachol (1 μM) 
induced a fast and long-duration contraction [23,24]. 
The leukotrienes were added in a single administration 
15 minutes after the addition of carbachol during the 
relaxation experiments. Tissues were incubated with 
5 mM L-cysteine, an inhibitor of glycinase, 7 minutes 
before starting the experiments to reduce peptide 
degradation [20,25]. In preliminary experiments, L-
cysteine caused a transient, negligible contraction 
(Fig. 1), or relaxation, or neither contraction nor re-
laxation (data not shown). For studies using atropine 
and tetrodotoxin, the muscle strips were exposed to 
the indicated concentrations of these agents for 
6 minutes and 15 minutes, respectively, and then to 
the various concentrations of leukotrienes [23,24]. 
Only one cumulative concentration-contraction re-
sponse curve, with or without the cysteinyl leukotriene 
antagonist, tetrodotoxin or atropine, was constructed 
with each preparation in the experiments.
2.2. Data analysis
Results are expressed as mean ± standard error of 
the mean. Statistical evaluation was performed using 
non-paired Student’s t test. A value of p < 0.05 was 
considered statistically significant.
3. Results
3.1. Effects of leukotrienes on contraction 
of the guinea pig lower esophageal 
sphincter
To test the ability of leukotrienes to cause muscle 
contraction, transverse strips from isolated guinea 
pig lower esophageal sphincter were prepared and 
responses to cysteinyl leukotrienes, including LTC4, 
LTD4, LTE4, and the dihydroxy leukotriene, LTB4, were 
studied. In the lower esophageal sphincter strips, both 
LTD4 and LTC4 induced a slow- and long-duration mus-
cle contraction (Fig. 1). In terms of the maximal ten-
sion of contraction, LTD4 and LTC4 had equal efficacy 
(Fig. 2). LTD4 caused a detectable contraction of the 
sphincter strips at 0.1 nM, half-maximal contraction 
at 4 ± 2 nM and maximal contraction at 1 μM. The max-
imal tension caused by 1 μM LTD4 was 29 ± 5% of the 
tension caused by 1 μM carbachol. LTC4 was as potent 
as LTD4, causing half-maximal contraction at 10 ± 5 nM 
and maximal contraction at 1 μM. LTE4 was less effica-
cious and less potent than LTD4. LTE4 caused a detect-
able contraction at 10 nM, half-maximal contraction of 
the sphincter strips at 160 ± 50 nM (p < 0.05, compared 
with LTD4; Fig. 2) and maximal contraction at 1 μM. 
LTE4, 1 μM, caused a contractile response of 14 ± 3% 
of the tension caused by 1 μM carbachol (p < 0.05, 
compared with LTD4; Fig. 2). In contrast, the dihydroxy 
leukotriene LTB4 did not cause contraction at concen-
trations up to 1 μM (Fig. 2).
In the carbachol (1 μM)-contracted lower esopha-
geal sphincter strips, LTD4, up to 1 μM, did not cause 
relaxation (data not shown).
2 min
1 g
L-cysteine 5 mM LTD4 0.1 1 10 100 1000 nM
Fig. 1 — A typical tracing showing the contraction of the 
guinea pig lower esophageal sphincter strip with cumulative 
addition of leukotriene LTD4.
Fig. 2 — Ability of leukotrienes, LTC4, LTD4, and LTE4 to 
cause contraction of the guinea pig lower esophageal 
sphincter. LTB4 did not cause contraction up to 1 mM. Values 
are expressed as the percent of carbachol (1 mM)-induced 
tone. Results given are from at least three experiments. 
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3.2. Effects of CysLT receptor antagonists 
on LTD4-induced lower esophageal 
sphincter contraction
To further characterize the CysLT receptors mediating 
the lower esophageal sphincter contraction, the abilities 
of two selective CysLT1 receptor antagonists, monte-
lukast and zafirlukast, and the dual CysLT1 and CysLT2 
receptor antagonist BAY u9773, to inhibit LTD4-induced 
contraction were determined.
Montelukast (1 μM), zafirlukast (1 μM) and BAY u9773 
(1 μM) alone did not cause contraction (data not shown) 
in the strips. As shown in Fig. 3, montelukast (1 μM) 
and zafirlukast (1 μM) shifted the LTD4 concentration-
response curve to the right. The tensions caused by 
1 μM LTD4 plus montelukast (1 μM) and zafirlukast (1 μM) 
were 12 ± 4% and 12 ± 2%, respectively, of the tension 
caused by 1 μM carbachol (p < 0.05, compared with 1 μM 
LTD4 alone). Similarly, the dual CysLT1 and CysLT2 
receptor antagonist BAY u9773 (1 μM) also shifted the 
LTD4 concentration-response curve to the right. The 
tension caused by 1 μM LTD4 plus BAY u9773 (1 μM) 
was 8.3 ± 2.3% of the tension caused by 1 μM carba-
chol (p < 0.05, compared with 1 μM LTD4 alone). The 
combination of both montelukast and BAY u9773 
shifted the LTD4 concentration-response curve to the 
right but did not potentiate the shift caused by mon-
telukast alone. The tension caused by 1 μM LTD4 plus 
both montelukast (1 μM) and BAY u9773 (1 μM) was 
12 ± 1% of the tension caused by 1 μM carbachol (p > 
0.05, compared with 1 μM LTD4 plus montelukast, 
1 μM; Fig. 3).
3.3. Effects of tetrodotoxin and atropine 
on LTD4-induced lower esophageal 
sphincter contraction
In the lower esophageal sphincter strips, the LTD4-
induced contraction was not affected by tetrodotoxin 
or atropine, at concentrations of 1 μM each (Fig. 4).
4. Discussion
In the present study, we have shown for the first time 
that cysteinyl leukotrienes elicit contraction in the 
guinea pig lower esophageal sphincter and CysLT1 
mediates this contraction. In addition, this study pro-
vides evidence that the dihydroxy leukotriene LTB4 
does not cause contraction of the lower esophageal 
sphincter.
Similar to a previous study on the contractile effect 
of LTD4 in cat lower esophageal sphincter muscle cells 
[20], this study demonstrated that LTD4 causes con-
tractions in guinea pig lower esophageal sphincter 
strips. In addition, this study showed that LTC4 and LTE4 
cause contractions in the guinea pig lower esophageal 
sphincter. LTC4 and LTD4 were of the same potency and 
efficacy whereas LTE4 was a partial agonist. Similar to 
that in the guinea pig gallbladder, the relative potencies 
for cysteinyl leukotrienes to cause contraction of the 
lower esophageal sphincter were LTD4 = LTC4 > LTE4 
[4,18]. In addition, the LTD4-induced contraction was 
inhibited by two selective CysLT1 receptor antagonists, 
montelukast and zafirlukast, and by the dual CysLT1 
and CysLT2 receptor antagonist BAY u9773. Furthermore, 
the combination of both montelukast and BAY u9773 
did not potentiate the inhibition caused by montelukast 
alone. These findings indicate that CysLT1 mediates this 
contraction in the lower esophageal sphincter, similar 
Fig. 3 — Ability of cysteinyl leukotriene receptor antago-
nists to inhibit leukotriene LTD4-induced contraction in 
the guinea pig lower esophageal sphincter. Values are 
expressed as the percent of carbachol (1 mM)-induced tone. 
Results given are from at least three experiments. Vertical 
































Fig. 4 — Ability of cysteinyl leukotriene LTD4 in the absence 
or presence of tetrodotoxin or atropine, 1 mM, to cause 
contraction of the guinea pig lower esophageal sphinc-
ter. Values are expressed as the percent of carbachol 
(1 mM)-induced tone. Results given are from at least three 
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to the guinea pig gallbladder [18,19]. In contrast, the 
dihydroxy leukotriene LTB4 did not cause contraction 
in the lower esophageal sphincter. This suggests that 
leukotriene LTB4 receptors are not involved in the 
contraction of the lower esophageal sphincter.
We demonstrated that the contractile response of 
the guinea pig lower esophageal sphincter to LTD4 was 
insensitive to atropine and tetrodotoxin, similar to 
studies showing the same responses in guinea pig 
gallbladder [18,19]. These findings indicate that indirect 
neural mechanisms are probably not involved and 
suggest a direct effect of cysteinyl leukotrienes on the 
lower esophageal sphincter muscle.
In the lower esophageal sphincter, LTC4, LTD4 and 
LTE4 induce contractions and CysLT1 mediates con-
tractions. Thus cysteinyl leukotrienes might play an 
important role in the control of lower esophageal sphinc-
ter motility. Studies on the endogenous release of 
these cysteinyl leukotrienes in the esophagus and on 
the role of cysteinyl leukotrienes in the human lower 
esophageal sphincter are warranted. Cysteinyl leuko-
trienes have been implicated in inflammatory condi-
tions, including eosinophilic esophagitis and eosinophilic 
gastroenteritis [1–3,15,16]. The high pressure of the 
lower esophageal sphincter in patients with eosinophilic 
esophagitis might be caused by cysteinyl leukotrienes 
released by eosinophils [26]. On the other hand, be-
cause CysLT1 antagonists influence lower esophageal 
sphincter motility, the use of CysLT1 receptor antag-
onists for treating asthma or other diseases might 
decrease lower esophageal sphincter contraction 
and worsen gastroesophageal reflux.
In conclusion, these results demonstrate that cys-
teinyl leukotrienes, but not the dihydroxy leukotriene 
LTB4, elicit contraction of the guinea pig lower esoph-
ageal sphincter. CysLT1 mediates this contraction.
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